Vanguard Group Inc Cytokinetics Inc Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 11,761,605 shares of CYTK stock, worth $575 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,761,605
Previous 11,437,696
2.83%
Holding current value
$575 Million
Previous $620 Million
0.21%
% of portfolio
0.01%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding CYTK
# of Institutions
409Shares Held
125MCall Options Held
4.6MPut Options Held
2.43M-
Black Rock Inc. New York, NY14.7MShares$717 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$474 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$380 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$316 Million0.01% of portfolio
-
Bank Of America Corp Charlotte, NC4.83MShares$236 Million0.02% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.6B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...